Novel non-steroidal anti-androgens (NSAA) are increasingly part of the management of prostate cancer. We aimed to quantify and compare the neurologic side effects of NSAA agents.
Phase III randomized controlled trials evaluating NSAAs in the treatment of prostate cancer were selected by two reviewers independently in MEDLINE.
A random-effects model and the Mantel-Haenszel method were used. The Odds Ratio (OR) and its 95% confidence interval were computed. The primary endpoints were the rates of neurologic adverse events.
Eight phase III trials evaluating novel NSAAs (vs. non-NSAAs) were included. Fatigue (OR:1.66 [1.32-2.08]), falls (OR:1.76 [1.25-2.49]), headache (OR:1.74 [1.42-2.14]), and dizziness (OR:1.70 [1.33-2.19]) were found to be significantly associated with NSAA use.
NSAAs are associated with an increase in various neurologic adverse events. When NSAAs are prescribed, neurologic adverse event prevention and management strategies should be discussed and implemented.
Critical reviews in oncology/hematology. 2021 Aug 27 [Epub ahead of print]
Ziad Bakouny, Emre Yekedüz, David A Braun, Jacob E Berchuck, Laure Hirsch, Güngör Utkan, Yi Lee, Quoc-Dien Trinh, Toni K Choueiri, Yüksel Ürün
Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States. Electronic address: ., Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey; Ankara University Cancer Research Institute, Ankara, Turkey. Electronic address: ., Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States. Electronic address: ., Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States. Electronic address: ., Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States. Electronic address: ., Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey; Ankara University Cancer Research Institute, Ankara, Turkey. Electronic address: ., Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States. Electronic address: ., Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States; Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States. Electronic address: ., Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States. Electronic address: ., Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey; Ankara University Cancer Research Institute, Ankara, Turkey. Electronic address: .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/34461269